

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Mushrooms, Inc.

23150 Fashion Drive
Estero, FL 33928

(239) 273-1194
info@mushroomsinc.com
2833

Quarterly Report

For the period ending September 30, 2025 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

39,435,760 as of September 30, 2025

39,435,760 as of June 30, 2025

39,435,760 as of March 31, 2025

39,435,760 as of December 31, 2024

39,435,760 as of September 30, 2024

39,435,760 as of June 30, 2024

39,435,760 as of March 31, 2024

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act),

directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

On March 8, 2018, the Company amended its Articles of Incorporation to change its name from Majestic Oil & Gas, Inc. to Majestic Group Holdings, Inc.

On January 18, 2019, the Company amended its Articles of Incorporation to change its name from Majestic GroupHoldings, Inc. to SecurCapital Holdings Corp.

On January 29, 2021, the Company amended its Articles of Incorporation to change its name from SecurCapital HoldingsCorp. To Marijuana Strategic Ventures, Inc.

On June 28, 2022, the Company amended its Articles of Incorporation to change its name from Marijuana Strategic Ventures, Inc. to Mushrooms, Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company was formed on April 16, 2002 as a Nevada corporation and has not changed corporate jurisdiction since inception. The Company's current standing as of the date of this filing with the Nevada Secretary of State is active.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

The address(es) of the issuer's principal executive office:

23150 Fashion Drive, Suite 231, Estero, FL 33928

The address(es) of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

23150 Fashion Drive, Suite 231, Estero, FL 33928

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Transfer Online
Phone: (503) 227-2950
Email: info@transferonline.com
Address: 512 SE Salmon Street, Portland, OR 97214

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

| | | |
|--|---------------------|----------------------------|
| Trading symbol: | <u>MSRM</u> | |
| Exact title and class of securities outstanding: | <u>Common Stock</u> | |
| CUSIP: | <u>81737X 106</u> | |
| Par or stated value: | <u>Par \$0.001</u> | |
| Total shares authorized: | <u>400,000,000</u> | as of date: <u>9/30/25</u> |
| Total shares outstanding: | <u>39,435,760</u> | as of date: <u>9/30/25</u> |
| Total number of shareholders of record: | <u>127</u> | as of date: <u>9/30/25</u> |

All additional class(es) of publicly quoted or traded securities (if any): None.

Other classes of authorized or outstanding equity securities:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

| | | |
|---|---------------------------------|----------------------------|
| Exact title and class of the security: | <u>Series A Preferred Stock</u> | |
| CUSIP (if applicable): | <u>Not applicable.</u> | |
| Par or stated value: | <u>\$0.001 per share.</u> | |
| Total shares authorized: | <u>10,000,000</u> | as of date: <u>9/30/25</u> |
| Total shares outstanding (if applicable): | <u>3,500,000</u> | as of date: <u>9/30/25</u> |
| Total number of shareholders of record (if applicable): | <u>3</u> | as of date: <u>9/30/25</u> |

| | | |
|---|---|----------------------------|
| Exact title and class of the security: | <u>Series B Convertible Preferred Stock</u> | |
| CUSIP (if applicable): | <u>Not applicable.</u> | |
| Par or stated value: | <u>\$0.001</u> | |
| Total shares authorized: | <u>2,000,000</u> | as of date: <u>9/30/25</u> |
| Total shares outstanding (if applicable): | _____ | as of date: _____ |
| Total number of shareholders of record (if applicable): | _____ | as of date: _____ |

| | |
|---|---|
| Exact title and class of the security: | <u>Series C Preferred Stock</u> |
| CUSIP (if applicable): | <u>Not applicable.</u> |
| Par or stated value: | <u>\$0.001</u> |
| Total shares authorized: | <u>2,000,000</u> as of date: <u>9/30/25</u> |
| Total shares outstanding (if applicable): | _____ as of date: _____ |
| Total number of shareholders of record (if applicable): | _____ as of date: _____ |

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

COMMON STOCK

1. General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the board of directors of the Corporation (the "Board of Directors") upon any issuance of the Preferred Stock of any series.
2. Voting.
 - a. The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being entitled to one vote for each share thereof held by such holder; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to these Articles of Incorporation (which, as used herein, shall mean the Articles of Incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to these Articles of Incorporation or the NRS. There shall be no cumulative voting in the election of directors or on any other matter.
 - ii. Except as may otherwise be provided by applicable law, in these Articles of Incorporation or in a Preferred Stock Designation (as defined below), the holders of shares of Common Stock shall have the exclusive right to vote for the election of directors and for all other purposes, and holders of shares of Preferred Stock and any series thereof shall not be entitled to receive notice of any meeting of stockholders at which they are not otherwise entitled to vote.
 - iii. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock of the Corporation entitled to vote thereon, voting as a single class, irrespective of the provisions of Section 78.390 of the NRS.
3. Dividends. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors and subject to any preferential dividend or other rights of any then outstanding Preferred Stock and to the requirements of applicable law.
4. Liquidation. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding Preferred Stock.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A Preferred Stock

Dividend: Upon approval by the board of directors, a dividend may be established, which may be paid in common stock or as a cash dividend. No dividend established as of this reporting period or date.

Voting: Each share of Series A Preferred Stock has the right to vote 1,000 votes per share on matters brought to a vote of the common shareholders.

Conversion: Each share of Series A Preferred Stock is convertible at the holder's option into 1 share of common stock.

Liquidation: Holders of Series A Preferred Stock are entitled to receive cash from the issuer's assets, before any amounts paid to holders of common stock, at the rate of \$0.001 per share.

Redemption: The company may redeem Series A Preferred Shares at the rate of \$0.001 per share, forcing the conversion of the shares of Series A Preferred Shares to common stock.

Sinking Fund: None established.

Series B Preferred Stock

Dividend: No dividend rights.

Voting: Series B Convertible Preferred Stock has no right to vote on matters brought to a vote of the common shareholders, but so long as any shares of Series B Convertible Preferred Stock are outstanding, no vote may be taken to adversely affect the rights of the Series B Convertible Preferred Stock holders.

Conversion: Each share of Series A Preferred Stock is convertible at the holder's option into 150 shares of common stock.

Liquidation: No liquidation rights.

Redemption: No redemption rights.

Sinking Fund: None established.

Series C Convertible Preferred Stock

Dividend: No dividend rights.

Voting: Series C Preferred Stock has no right to vote on matters brought to a vote of the common shareholders, but so long as any shares of Series B Convertible Preferred Stock are outstanding, no vote may be taken to adversely affect the rights of the Series B Convertible Preferred Stock holders.

Conversion: Each share of Series A Preferred Stock is convertible at the holder's option into 250 shares of common stock.

Liquidation: No liquidation rights.

Redemption: No redemption rights.

Sinking Fund: None established.

3. Describe any other material rights of common or preferred stockholders.

None.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

| Shares Outstanding as of Second Most Recent Fiscal Year End: | | | *Right-click the rows below and select "Insert" to add rows as needed. | | | | | | |
|---|--|--|--|---|--|--|--|---|---------------------------------|
| Opening Balance | | | | | | | | | |
| Date <u>12/31/2024</u> Common: <u>39,435,760</u> Preferred: <u>3,500,000</u> | | | | | | | | | |
| Date of Transaction | Transaction type (e.g., new issuance, cancellation, shares returned to treasury) | Number of Shares Issued (or cancelled) | Class of Securities | Value of shares issued (\$/per share) at Issuance | Were the shares issued at a discount to market price at the time of issuance? (Yes/No) | Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed. | Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided | Restricted or Unrestricted as of this filing. | Exemption or Registration Type. |
| <u>January 10, 2023</u> | <u>New Issuance</u> | <u>1,000,000</u> | <u>Common</u> | <u>\$0.0250</u> | <u>Yes</u> | <u>Nicole Fey</u> | <u>Cash</u> | <u>Restricted</u> | <u>Rule 144</u> |
| <u>March 22, 2023</u> | <u>New Issuance</u> | <u>69,037</u> | <u>Common</u> | <u>\$0.0235</u> | <u>No</u> | <u>Cory Bataan</u> | <u>Investor Relations Services</u> | <u>Restricted</u> | <u>Rule 144</u> |
| <u>March 22, 2023</u> | <u>New Issuance</u> | <u>69,037</u> | <u>Common</u> | <u>\$0.0235</u> | <u>No</u> | <u>John Grosso</u> | <u>Investor Relations Services</u> | <u>Restricted</u> | <u>Rule 144</u> |

| | | | | | | | | | |
|-----------------------|---------------------|----------------|---------------|-----------------|-----------|------------------------|-----------------------------|-------------------|-----------------|
| <u>March 22, 2023</u> | <u>New Issuance</u> | <u>200,000</u> | <u>Common</u> | <u>\$0.0235</u> | <u>No</u> | <u>Richard Hawkins</u> | <u>Consulting Services</u> | <u>Restricted</u> | <u>Rule 144</u> |
| <u>July 7, 2023</u> | <u>New Issuance</u> | <u>250,000</u> | <u>Common</u> | <u>\$0.25</u> | <u>No</u> | <u>Hyder Ali Khoja</u> | <u>Consulting Agreement</u> | <u>Restricted</u> | <u>Rule 144</u> |

| | | | | | | | | | |
|---------------------------|---------------------|----------------|---------------|---------------|------------|------------------------------------|-----------------------------|-------------------|-----------------|
| <u>July 7, 2023</u> | <u>New Issuance</u> | <u>250,000</u> | <u>Common</u> | <u>\$0.25</u> | <u>No</u> | <u>David A. Flores</u> | <u>Consulting Agreement</u> | <u>Restricted</u> | <u>Rule 144</u> |
| <u>September 8, 2023</u> | <u>New Issuance</u> | <u>250,000</u> | <u>Common</u> | <u>\$0.03</u> | <u>Yes</u> | <u>SRFL.LTD (David A. DiMarco)</u> | <u>Cash</u> | <u>Restricted</u> | <u>Rule 144</u> |
| <u>September 8, 2023</u> | <u>New Issuance</u> | <u>250,000</u> | <u>Common</u> | <u>\$0.03</u> | <u>Yes</u> | <u>Nicole Fey</u> | <u>Cash</u> | <u>Restricted</u> | <u>Rule 144</u> |
| <u>September 8, 2023</u> | <u>New Issuance</u> | <u>200,000</u> | <u>Common</u> | <u>\$0.25</u> | <u>No</u> | <u>Maqsad Suriev</u> | <u>Consulting Agreement</u> | <u>Restricted</u> | <u>Rule 144</u> |
| <u>September 11, 2023</u> | <u>New Issuance</u> | <u>250,000</u> | <u>Common</u> | <u>\$0.25</u> | <u>No</u> | <u>Alicia Fantozzi</u> | <u>Consulting Agreement</u> | <u>Restricted</u> | <u>Rule 144</u> |

Shares Outstanding on Date of This Report:

Ending Balance:

Date March 31, 2025

Common: 39,435,760

Preferred: 2,500,000

Example: A company with a fiscal year end of December 31st, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2021 through December 31, 2022 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: (If yes, you must complete the table below)

| Date of Note Issuance | Outstanding Balance (\$) | Principal Amount at Issuance (\$) | Interest Accrued (\$) | Maturity Date | Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares) | Name of Noteholder. *You must disclose the control person(s) for any entities listed. | Reason for Issuance (e.g. Loan, Services, etc.) |
|------------------------------|---------------------------------|--|------------------------------|----------------------|---|---|--|
| | | | | | | | |

| | | | | | | | |
|---------|---------|----------|-----|-------------------------|------------------------------|----------------------|---------------|
| 12/4/17 | \$1,575 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Don Steinberg | Debt Purchase |
| 12/4/17 | \$1,575 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Robert L. Hymers III | Debt Purchase |
| 12/4/17 | \$14 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Jayne Littman | Debt Purchase |

| | | | | | | | |
|---------|-----|----------|-----|-------------------------|------------------------------|----------------------|---------------|
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | James Grimard | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Caren Glasser | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Steven Magida | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Michael Peskin | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Dale Johnson | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Arielle Tolchin | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Robert L. Hymers III | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Nadeen Elfarra | Debt Purchase |
| 12/4/17 | \$7 | \$22,950 | \$0 | Past Due as of 12/10/18 | Converts at \$.001 per share | Joel Tolchin | Debt Purchase |

Use the space below to provide any additional details, including footnotes to the table above:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. (Please ensure that these descriptions are updated on the Company's Profile on www.otcmarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

B. List any subsidiaries, parent company, or affiliated companies.

C. Describe the issuers' principal products or services.

5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company does not lease or own an office, any real estate or assets as of the quarter ended September 30, 2022, and as of the date of this filing. The Company's offices are located in spaces provided to the Company free of charge by an affiliate, located at 23150 Fashion Drive Suite 231, Estero FL, 33928.

6) Officers, Directors, and Control Persons

| Name of Officer/Director or Control Person | Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%) | Residential Address (City / State Only) | Number of shares owned | Share type/class | Ownership Percentage of Class Outstanding | Note |
|--|---|---|------------------------|---------------------------------|---|--|
| James Hancock | Owner of more than 5% | San Diego, CA | <u>2,319,723</u> | <u>Common</u> | <u>5.88%</u> | |
| Earth Onyx LLC (Donald Steinberg) | Sole Director, Owner of more than 5% | Bonsall, CA | <u>1,000,000</u> | <u>Series A Preferred Stock</u> | <u>28.57%</u> | <u>Representing 28.57% of Issuer's outstanding voting power, issued on March 2, 2022</u> |

| | | | | | | |
|--|--------------------------------------|--------------------|------------------|---------------------------------|---------------|--|
| Kimberly Carlson | CEO, CFO, Owner of more than 5% | Estero, FL | <u>2,000,000</u> | <u>Series A Preferred Stock</u> | <u>57.14%</u> | <u>Representing 28.57% of Issuer's outstanding voting power, issued on April, 2024</u> |
| Dianna Kaplan | Owner of more than 5% | St. Martin, France | <u>500,000</u> | <u>Series A Preferred Stock</u> | <u>14.29%</u> | <u>Representing 14.29% of Issuer's outstanding voting power, issued on January 4, 2021</u> |
| Earth Onyx LLC (Donald Steinberg) | Sole Director, Owner of more than 5% | Bonsall, CA | <u>4,176,500</u> | <u>Common Stock</u> | <u>10.59%</u> | |
| Donald Steinberg | Sole Director, Owner of more than 5% | Bonsall, CA | <u>5,050,000</u> | <u>Common Stock</u> | <u>12.81%</u> | |
| Blue Ridge Enterprises, LLC (Donald Steinberg) | Sole Director, Owner of more than 5% | Bonsall, CA | <u>1,673,584</u> | <u>Common Stock</u> | <u>4.24%</u> | |
| Dianna Kaplan | Owner of more than 5% | St. Martin, France | <u>3,103,125</u> | <u>Common Stock</u> | <u>7.87%</u> | |
| Robert Hymers | Owner of more than 5% | Glendale, CA | <u>1,214,052</u> | <u>Common Stock</u> | <u>5.08%</u> | |
| Pinnacle Consulting Services Inc (Robert Hymers) | Owner of more than 5% | Glendale, CA | <u>2,500,000</u> | <u>Common Stock</u> | <u>6.34%</u> | |
| Zawi Now LLC (Kimberly Carlson) | CEO, CFO, Owner of more than 5% | Estero, FL | <u>4,170,000</u> | <u>Common Stock</u> | <u>10.57%</u> | |

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuer's securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None.

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None.

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None.

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None.

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities..

None.

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None.

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None.

Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Alan T. Hawkins
Firm: INDEPENDENT LAW PLLC
Address 1: 2106 NW 4th Pl
Address 2: Gainesville, FL 32603
Phone: (352) 353-4048
Email: ahawkins@independent.law

Accountant or Auditor

Name: None

Investor Relations

Name: None.

All other means of Investor Communication:

Twitter/X: <https://twitter.com/MushroomsInc>
Discord: None
LinkedIn: None
Facebook: <https://www.facebook.com/shroomsinc/>
[Other] <https://www.instagram.com/mushroomsforhealth/>

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: None.

8) Disclosure & Financial Info

A. This Disclosure Statement was prepared by (name of individual):

Name: Donald Steinberg
Title: Board Director
Relationship to Issuer: Director

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual)²:

Name: Donald Steinberg
Title: Board Director
Relationship to Issuer: Director

Describe the qualifications of the person or persons who prepared the financial statements: Donald Steinberg has been CEO and board director of public companies for over 15 years.

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.

- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

9) Issuer Certification

⁵The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Kimberly Carlson, certify that:

1. I have reviewed this Disclosure Statement for Mushrooms, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 30, 2025

/s/ Kimberly Carlson [CEO's Signature]

(Digital Signatures should appear as "/S/ [OFFICER NAME]")

Principal Financial Officer:

I, Kimberly Carlson, certify that:

1. I have reviewed this Disclosure Statement for Mushrooms, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 30, 2025

/s/ Kimberly Carlson [CFO's Signature]

(Digital Signatures should appear as "/S/ [OFFICER NAME]")

Mushrooms, Inc. (F/K/A: Marijuana Strategic Ventures Inc.)
Consolidated Balance Sheets (Unaudited)

| | September | September |
|--|------------------------|------------------------|
| | <u>2025</u> | <u>2024</u> |
| ASSETS | | |
| Current Assets: | | |
| Cash | \$53 | \$477 |
| Inventory | 8,226 | 8,754 |
| Prepaid Expenses | 0 | 11,716 |
| Prepaid Taxes | 0 | 4,304 |
| Deposit | <u>0</u> | <u>0</u> |
| Total Current Assets | <u>8,279</u> | <u>25,251</u> |
| Intangible Assets Intellectual Property | <u>5,771</u> | <u>1,534</u> |
| TOTAL ASSETS | <u>\$14,050</u> | <u>\$26,785</u> |
| LIABILITIES & STOCKHOLDERS' EQUITY | | |
| Current Liabilities: Accounts Payable | 3310 | 52704 |
| Accrued/Deferred Liabilities | 0 | 18,860 |
| Convertible Promissory Notes, net | 3,227 | 3,227 |
| Due To/From Kimberly Carlson | 0 | 3,775 |
| Due To/From James Hancock/JBG | 10,000 | 16,042 |
| Due To/From Blue Ridge | 0 | 14,732 |
| Due To/From Donald Steinberg | 1,400 | 19,187 |
| Due To/From Robert Hymers | 11,860 | 9,000 |
| Due to Nicole Breen | 3,780 | - |
| Due to Gary Blum | 1,200 | - |
| Due to Matt Dwyer | 4,500 | - |
| Deferred Revenue | 0 | 35 |
| Long Term loan from shareholders | | 50 |
| Other Liabilities | <u>723</u> | <u>17,733</u> |
| Total Current Liabilities | <u>40,000</u> | <u>155,345</u> |
| Long term Liabilities | | |
| Equity Loan-Oscura Insights | <u>25,000</u> | <u>25,000</u> |
| Total Long-Term Liabilities | <u>25,000</u> | <u>25000</u> |
| Total Liabilities | <u>65,000</u> | <u>180,345</u> |
| Stockholders' Equity: | | |
| Preferred Stock; \$0.001 par value; 1,500,000 shares issued | 3,500 | 1,500 |
| Common Stock; \$0.001 par value; 400,000,000 shares authorized; | 39,436 | 39436 |
| Additional Paid-In Capital | 2,188,547 | 2,356,910 |
| Accumulated deficit | <u>-2,282,433</u> | <u>-2,551,356</u> |
| Total stockholder's equity | <u>-50,950</u> | <u>-153,510</u> |
| TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT | <u>\$14,050</u> | <u>\$26,835</u> |

See Note 2A — Prior-Period Revisions and Reclassifications (2024 Comparatives).

Mushrooms, Inc. (F/K/A: Marijuana Strategic Ventures Inc.)
Consolidated Statements of Operations (Unaudited)

| | For the Three Months Ended September 30, | |
|--|---|------------------------|
| | 2025 | 2024 |
| Sales Revenue | 2144.56 | 649.1 |
| Cost of Goods Sold | 1212 | 428.7 |
| Gross Profit | <u>932.56</u> | <u>220.4</u> |
| <u>Expenses:</u> | | |
| General (rent, meals, Phone, SOS) & Administrative | 457.06 | 3425.27 |
| Advertising and Marketing | 24 | 625.13 |
| Research and Development | 0 | 0 |
| Amortization | 533.5 | 1448 |
| Professional and Legal Fees | 4,500 | 25 |
| Salaries and Wages | 0 | 0 |
| Consulting Expenses | <u>0</u> | <u>0</u> |
| Total Operating Expenses | <u>5,514.56</u> | <u>5,523.40</u> |
| Operating Loss | -4,582 | -5,303 |
| <u>Other Income (Expense)</u> | | |
| Miscellaneous Other Income (Expense) | 0 | 0 |
| Total Other Income (Expense) | 0 | 0 |
| Net Loss | <u>(\$4,582)</u> | <u>(\$5,303)</u> |
| Basic and diluted loss per common share | <u>(\$0.00)</u> | <u>(\$0.01)</u> |
| Weighted average common shares outstanding | <u>39,435,760</u> | <u>39,435,760</u> |

See Note 2A — Prior-Period Revisions and Reclassifications (2024 Comparatives).

Mushrooms, Inc. (F/K/A: Marijuana Strategic Ventures Inc.)
Consolidated Statements of Cash Flows (Unaudited)

| | For the Three Months Ended September 30, | |
|--|---|--------------------|
| | <u>2025</u> | <u>2024</u> |
| Cash Flow From Operating Activities | 0 | 0 |
| Net Loss | (\$4,582) | (\$5,303) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Stock Based Compensation for Director | 0 | 0 |
| Issuance of Common Stock for Services | 0 | 0 |
| Stock Based Compensation for Director | 0 | 0 |
| Amortization Expense | 534 | 1,448 |
| long-term loan from shareholders | | 0 |
| Changes in working capital | | |
| Decrease in Inventory | 0 | 0 |
| Increase (decrease) in Accounts Payable | 1,152 | 4,033 |
| Increase in Due To/From Kimberly Carlson | 0 | 379 |
| Decrease in Due To/From James Hancock | 0 | 0 |
| Increase in Due To/From Blue Ridge | 0 | 0 |
| Increase (decrease) in Due To/From Donald Steinberg | 1,300 | 0 |
| Increase in Due To/From Robert Hymers | 1600 | 0 |
| Net Cash Used in Operating Activities | <u>4</u> | <u>556</u> |
| Cash Flow From Investing Activities | <u>0</u> | <u>0</u> |
| Net Cash Used in Investing Activities | <u>0</u> | <u>0</u> |
| Cash Flow From Financing Activities | 0 | |
| Proceeds from Issuance of Common Stock | 0 | 0 |
| Proceeds from Equity Loan | 0 | 0 |
| Net Cash Provided by Financing Activities | <u>0</u> | <u>0</u> |
| Net Change in Cash | 4 | 556.34 |
| Cash at Beginning of Period | 49 | 68.27 |
| Cash at End of Period | <u>53</u> | <u>624.61</u> |
| Net cash paid for: | 0 | 0 |
| Interest | 0 | 0 |
| Income Taxes | <u>0</u> | <u>0</u> |

See Note 2A — Prior-Period Revisions and Reclassifications (2024 Comparatives).

Consolidated Statements of Stockholders' Equity

| Description | Class A Preferred Stock | | Common Stock | | Additional Paid-in Capital | Accumulated Deficit | Total |
|------------------------------------|-------------------------|----------------|---------------------|-----------------|----------------------------|----------------------|--------------------|
| | Shares | Amount | Shares | Amount | | | |
| Balance, December 31, 2022 | \$1,500,000 | \$1,500 | \$36,647,686 | \$36,648 | \$2,033,277 | (\$2,227,549) | (\$156,125) |
| Issuance of Stock for Cash | | | \$1,500,000 | \$1,500 | \$38,500 | | \$40,000 |
| Issuance of Stock for Compensation | | | \$1,288,074 | \$1,288 | \$82,320 | | \$83,608 |
| Net Loss | | | | | | (\$39,876) | (\$39,876) |
| Prior Period Adjustment | | | | | | | |
| Balance, December 31, 2023 | \$1,500,000 | \$1,500 | \$39,435,760 | \$39,436 | \$2,154,097 | (\$2,267,425) | (\$72,393) |
| Issuance of Preferred Stock | \$2,000,000 | \$2,000 | | | \$34,450 | | \$36,450 |
| Net Loss | | | | | | (\$10,641) | (\$10,641) |
| Balance, December 31, 2024 | \$3,500,000 | \$3,500 | \$39,435,760 | \$39,436 | \$2,188,547 | (\$2,278,066) | (\$46,584) |
| Issuances | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| Net Loss | \$0 | \$0 | \$0 | \$0 | \$0 | (\$702) | (\$702) |
| Balance, March 31, 2025 | \$3,500,000 | \$3,500 | \$39,435,760 | \$39,436 | \$2,188,547 | (\$2,278,767) | (\$47,286) |
| Issuances | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| Net Loss | \$0 | \$0 | \$0 | \$0 | \$0 | (\$4,582) | (\$4,582) |
| Balance, September 30, 2025 | \$3,500,000 | \$3,500 | \$39,435,760 | \$39,436 | \$2,188,547 | (\$2,283,349) | (\$51,868) |

See Note 2A — Prior-Period Revisions and Reclassifications (2024 Comparatives).

Mushrooms, Inc. (f/k/a: Marijuana Strategic Venture Inc.)

Notes to the Financial Statements
For the period ended September 30, 2025

NOTE 1 - ORGANIZATION AND OPERATIONS

Current Operations

MSRM formally was a marijuana and cannabis business holding company developing a portfolio of subsidiaries operating in the legalized cannabis industry. We only operated in those states where cannabis was legalized and regulated under applicable state laws, and/or had been decriminalized for medical use and/or legalized for recreational use. Our strategy was to operate and expand our holdings in the legal cannabis industry through acquisition, joint venture, partnership, or investment. The Company was operated by an executive team that had significant experience in the cannabis industry and a robust operational and acquisition track-record as to all facets of the Company's operations, which had executed its business plan to rapidly scale its business.

On May 26, 2022, the Company began a process to change its corporate name to Mushrooms, Inc., and its stock symbol to MSRM.

The vision for Mushrooms, Inc. is to support the growth of the mushroom industry through collaboration, innovation, and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms, Inc. Our current focus is on the industrial application of Mycelium for the creation of carbon neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and Development is the path to achieving great innovation and the pioneers are the ones we look to for their fortitude and enduring dedication to the world of mycology. The working relationships we are fostering will result in scientifically proven products that advance health of body, mind, and environment.

Business Plan

Formally MSRM invested in geographically diverse licensed dispensaries, cultivation and processing facilities and other cannabis related companies that operated domestically and internationally. The Company's mission was to champion and provide private cannabis companies access to becoming a public company and give the owners and management increased value in their ownership. We had fostered strong partnerships with small, mid-size, and development-stage private businesses with the aim of setting a new standard for the marijuana industry. As legislation and regulations evolved, we believed we were poised to build on our leadership position by expanding our footprint and capabilities in bringing safe, affordable cannabis to the market. We deeply believed in the transformational power that marijuana had to heal and change the world.

Now since changing its name to Mushrooms, Inc., the vision for MSRM is to support the growth of the mushroom industry through collaboration, innovation, and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms, Inc. Our current focus is on the industrial application of Mycelium for the creation of carbon neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and Development is the path to achieving great innovation and the pioneers are the ones we look to for their fortitude and enduring dedication to the world of mycology. The working relationships we are fostering will result in scientifically proven products that advance health of body, mind, and environment.

Corporate Management

Kimberly Carlson – CEO and CFO

Kimberly Carlson has repeatedly created meaningful and lasting connections between business, community and the environment. She is able to find the mutually beneficial meeting point between the business and the consumer while always considering the environmental impact of actions taken. Her experiential marketing skills include creating proprietary live art performance events which have proven success in building the business and the brand. A belief that collaborations are essential has fueled her team building skills and employing creative minds has garnered much success for the businesses she has been integral in developing. Kimberly's education includes life experience from being employed since the age of 15 to launching her first successful business at age 20 and being awarded for her second business launch at age 22. Her formal education includes Columbia College Chicago for Public Relations and Marketing as well as Florida Gulf Coast University (FGCU) with a focus on lean start-up, product innovation, and business management through their, Princeton Review and Entrepreneur magazine top ranking, School of Entrepreneurship.

Don Steinberg – Chairman and sole member of the Board

Don has vast experience in building and managing start-up companies, managing public company compliance, and spent years managing floor operations on various stock exchanges. Mr. Steinberg has had a life-long career in international sales and marketing, with over 40 years of experience developing and running successful businesses. Using this breadth of experience, Don will provide guidance for the Company and is actively involved in its future and growth.

Donald Steinberg has been at the forefront of new business concepts many times and now brings a lifetime of experience to Mushrooms Inc., that will serve to benefit the company in a myriad of ways. In the 1980s, Don developed stock option analysis and trading programs, which led to his management of floor traders on multiple options exchanges and helped position him to successfully take other companies public.

In the early 1990s, he co-founded Globalcom 2000, entering the then-unknown prepaid phone card market. The company became one of the largest and fastest-growing phone card businesses in the U.S. In 1994, Don co-founded One World Communications, focusing on the international "callback" telecom sector. He opened 187 training centers in just 9 months and built what became the world's largest international MLM sales force for telecom services.

In 2006, Mr. Steinberg launched Club Vivanet, an international MLM platform offering a variety of services. By 2008, he merged Club Vivanet with a publicly traded company and pivoted the business into the emerging cannabis sector. He renamed the company Medical Marijuana Inc., making it the first public cannabis company in the U.S. In 2011, he led the acquisition and successful management transition of the company.

In 2022, he was the Founder and CEO of Marijuana Inc. Recognizing the changing landscape in the cannabis industry, in late 2024 he successfully merged the company with Exousia Pro, a biotech company.

Leadership Role:

As Director of Mushrooms Inc., Mr. Steinberg led the company through strategic transitions, including its repositioning in the public markets and advancement of new sector-related ventures. He remained actively involved in operational oversight, investor communications, and compliance with OTC Markets reporting standards.

Corporate History

Majestic Oil & Gas, Inc. (“Company”, “we”, “our”, or “MSVI”) was formed on April 16, 2002 as a Nevada corporation and operated in the oil production business until the first quarter of 2017, when the Company acquired Bakken Acquisition & Holdings, Inc. to acquire its license to a patented product for the remediation of subterranean organic contamination.

On March 8, 2018, the Company amended its Articles of Incorporation to change its name from Majestic Oil & Gas, Inc. to Majestic Group Holdings, Inc.

On January 18, 2019, the Company amended its Articles of Incorporation to change its name from Majestic Group Holdings, Inc. to SecurCapital Holdings Corp.

On January 29, 2021, the Company amended its Articles of Incorporation to change its name from SecurCapital Holdings Corp. to Marijuana Strategic Ventures, Inc.

On January 17, 2019, the Company filed amended Articles of Incorporation with the Secretary of State of the State of Nevada to change its corporate name from Majestic Oil & Gas, Inc., to SecurCapital Holdings Corp., and to implement a reverse split of the Company’s common stock at a ratio of 1:500. FINRA processed these actions with an effective date of April 29, 2019.

On March 10, 2019, our controlling shareholder, MJ Holdings, Inc., transferred 1,000,000 shares of the Company’s Series A Preferred Stock to Arielle Tolchin. As each share of the Company’s Series A Preferred Stock gives the holder the right to vote equivalent to 1,000 shares of the Company’s common stock per share of Series A Preferred Stock held, Ms. Tolchin acquired 1,000,000,000 votes, representing approximately 98.4% of the Company’s outstanding voting stock.

On January 17, 2019, the Company filed amended Articles of Incorporation with the Secretary of State of the State of Nevada to change its corporate name from Majestic Oil & Gas, Inc., to SecurCapital Holdings Corp., and to implement a reverse split of the Company’s common stock at a ratio of 1:500. FINRA processed these actions with an effective date of April 29, 2019. On May 29, 2019, the Company’s stock symbol was changed from MJOG to CQER.

On December 11, 2020, our sole director and controlling shareholder, Ms. Arielle Tolchin, resigned from her positions as Chief Executive Officer and as the Company’s sole director. On the same date, Ms. Tolchin appointed James Hancock as Chief Executive Officer, president, secretary and treasurer, and sole director of the Company.

On January 4, 2021, 1,000,000 shares of Series A Preferred Stock held by Arielle Tolchin were transferred to two persons: 500,000 shares of the Company’s Series A Preferred Stock were issued to Dianna Kaplan and another 500,000 shares of the Company’s Series A Preferred Stock were issued to Blue Ridge Enterprises LLC, an entity controlled by Donald Steinberg. As each share of the Company’s Series A Preferred Stock gives the holder the right to vote equivalent to 1,000 shares of the Company’s common stock per share of Series A Preferred Stock held, Kaplan and Blue Ridge Enterprises each acquired 500,000,000 votes, representing approximately 49.17% of the Company’s outstanding voting stock each.

On January 6, 2021, Daniel Witzel received 30,000 shares as compensation for \$16,000 in services pertaining to updating the corporate website.

On January 11, 2021, a financial consultant was issued 5,000,000 restricted common shares at a value of \$.03 as compensation for a consulting contract. The shares were deemed earned in full upon issuance.

On January 15, 2021, Arman Tabatabaei was appointed to the board of directors and was issued 1,200,000 shares valued at \$60,000 as compensation.

On January 25, 2021, the Company acquired all outstanding interests in MJOG and SecureCapital, Inc., a California corporation, in a related transaction from our CEO and CFO, James Hancock, for \$100.

On January 27, 2021, Blue Ridge Enterprises LLC received 5,000,000 common shares at \$.03 per share as compensation for a consulting agreement. On January 27, 2021, Donald Steinberg was appointed as a director of the Company.

On January 29, 2021, the Company filed amended Articles of Incorporation with the Secretary of State of the State of Nevada to change its corporate name from SecurCapital Holdings Corp. to Marijuana Strategic Ventures, Inc.

On June 14, 2021, FINRA processed this name change and a change in the Company's stock symbol from CQER to MVSI with publication in the daily list on June 11, 2021 and an effective date of June 14, 2021.

On April 19, 2021, Kimberly Borsa was issued 19,239 common shares at \$.0007 per share as compensation for conversion of convertible debt.

On June 16, 2021, Kimberly Borsa was issued 192,390 common shares at \$.0007 per share as compensation for conversion of convertible debt.

On August 30, 2021, 600,000 common shares previously issued to Arman Tabatabaei for services rendered to the Company as director, were cancelled per settlement agreement. On September 29, 2021, Donna Richardson was issued 100,000 common shares pursuant to a subscription agreement.

On September 29, 2021, Robert and Donna Richardson were issued 100,000 common shares pursuant to a subscription agreement.

On October 5, 2021, Robert Richardson received 125,000 common shares at \$.20 per share as compensation per consulting agreement. On October 19, 2021, Jeremy and Marilyn Virgin were issued 100,000 common shares pursuant to a subscription agreement.

On December 8, 2021, James Hancock received 2,186,250 common shares at \$.0007 per share as compensation for conversion of convertible debt.

On May 27, 2022, James Hancock resigned as CEO, CFO, Board Member, and Chairman of the Board, at which time he was appointed COO. Kimberly Carlson was appointed CEO and CFO, and Donald Steinberg was appointed Chairman and sole member of the Board of Directors.

On May 9, 2023, the Company filed a second certificate of amendment to the designations, preferences, and rights of the Company's series A preferred stock, the amendment being the series A preferred stock is now

convertible into common stock at a one-for-one basis.

On April 12, 2024 the company issued 2,000,000 shares of the Company's Series A Preferred Stock to Kimberly Carlson. As each share of the Company's Series A Preferred Stock gives the holder the right to vote equivalent to 1,000 shares of the Company's common stock per share of Series A Preferred Stock held, Kimberly Carlson acquired 2,000,000,000 votes, representing approximately 57.14% of the Company's outstanding voting stock.

In June 2025, the Company announced the acquisition of MYCOLabX as a wholly-owned subsidiary. No shares or cash consideration were issued, and there was no dilution to existing shareholders. MYCOLabX now holds (i) the Company's mycelium wound-care and textile intellectual property (including color-change infection-detection and nutrient-delivery textile technologies), (ii) the related revenue-share agreements, and (iii) the obligations previously associated with development of that IP, including revenue share agreements and the \$25,000 Oscura Insights LLC funding, which carries a revenue-based payout of up to \$75,000. The transaction consolidated the Company's IP program and related obligations into a single subsidiary to streamline development and commercialization.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading.

Notes to the financial statements that would substantially duplicate the disclosures contained in the annual financial statements for the most recent fiscal period, as reported in the Annual Report, have been omitted.

Recently Adopted Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 2A – PRIOR-PERIOD REVISIONS AND RECLASSIFICATIONS (2024 COMPARATIVES)

The 2024 comparative amounts presented herein differ from the Company's previously filed quarterly disclosure for the three months ended September 30, 2024. During preparation of these financial statements, management (i) corrected computational/subtotal errors, (ii) reclassified certain items to conform to the current-period presentation, and (iii) aligned presentation with the Company's amended annual reports for 2023 and 2024. These changes do not reflect new transactions.

Key revisions and reclassifications included:

- **Cash & cash flows (Q3-2024).** Beginning and ending cash were tied to bank statements (beginning **\$68.27**, ending **\$624.61**), resulting in a **net increase of \$556.34** for the quarter and corresponding adjustments to the operating cash-flow reconciliation (indirect method).
- **COGS and Gross Profit (Q3-2024).** The prior single caption "Cost of Goods Sold Gross Profit" was

separated into **Cost of Goods Sold** and **Gross Profit** to conform to current presentation.

- **Oscura Insights LLC balance.** The **\$25,000** Oscura balance is presented within **long-term liabilities** (consistent with the amended annuals), rather than within equity as previously presented.
- **Related-party and other liabilities.** Certain shareholder/related-party amounts previously aggregated or shown as long-term were reclassified into the current-liability captions (“Due to/From ...”) to improve comparability.

Comparative information is unaudited. Where necessary, components (e.g., retained earnings vs. net income) were adjusted so subtotals and totals foot to the corrected amounts.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The financial statements do not include any adjustment relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing.

NOTE 4 – INTANGIBLE ASSETS

As of September 30, 2025, the Company held intangible assets, net of amortization, of \$5,771. Amortization expense for the three months ended September 30, 2025 was \$533.50. The intangible assets consist of a logo, two websites developed by the Company during 2022, to be used for advertising and marketing purposes, as well as a couple of trademarks developed during the opening quarter of 2025.

NOTE 4A – MYCOLABX ACQUISITION (JUNE 2025)

In June 2025, the Company announced the acquisition/formation of MYCOLabX, a wholly-owned subsidiary. No shares or cash consideration were issued, and there was no dilution to existing shareholders. MYCOLabX now holds (i) the Company’s mycelium wound-care and textile intellectual property (including color-change infection-detection and nutrient-delivery textile technologies), (ii) the related revenue-share agreements, and (iii) the obligations associated with development of that IP, including the \$25,000 Oscura Insights LLC funding, which carries a revenue-based payout of up to \$75,000.

The transaction consolidated the Company’s IP program and related obligations into a single subsidiary to streamline development and commercialization. The transfer was accounted for at historical carrying amounts; no goodwill or purchase consideration was recognized. See Long-Term Liabilities for the Oscura balance and Note 4 — Intangible Assets for current-period amortization.

NOTE 5 – PREFERRED STOCK

Effective October 5, 2016, the Company filed an amendment to its articles of incorporation with the Nevada Secretary of State to authorize the designation and issuance of 10,000,000 shares of preferred stock. The Board of Directors is authorized to divide the 10,000,000 shares of preferred stock from time to time into one or more series, and to determine or change by resolution for each such series its designation, the number of shares of

such series, the powers, preferences and rights and the qualifications, limitations or restrictions for the shares of such series. The resolution or resolutions of the Board of Directors providing for the division of such preferred stock into series may include the provisions relating to the number of shares in each class or series, voting rights, dividend rights, redemption rights, dissolution rights, conversion rights and any other provisions regarding the powers, preferences and rights, and the qualifications, limitations or restrictions, for each such series which are not inconsistent with applicable law.

Effective October 26, 2016, the Company filed a certificate of designation with the Nevada Secretary of State to create a class of preferred shares named Series A Preferred Stock, with 1,000,000 shares authorized at \$0.001 par value per share and setting forth its respective rights, preferences and limitations. The holders of Series A Preferred Stock may at their option convert the shares of Series A Preferred Stock into shares of common stock on a one for one basis. Each holder of shares of Series A Preferred Stock shall be entitled to cast the equivalent of 1,000 common stock votes for each Series A Preferred Stock held of record. The Series A Preferred Stock are anti-dilutive to reverse splits, and therefore in the case of a reverse split, are convertible to the number of common shares after the reverse split as would have been equal to the conversion rate of one to one. The Corporation may redeem the Series A Preferred Stock by providing a five-day notice to the holder of the Series A Preferred Shares and then redeem such Series A Preferred Shares at a redemption price of \$0.001.

The Series A Preferred Stock was amended on June 5, 2018 via an amended certificate of designation filed with the Nevada Secretary of State. This amended designation established that the Series A Preferred Stock was convertible into 1,000 shares of common stock per share of Series A Preferred Stock converted, and that each holder of shares of Series A Preferred Stock shall be entitled to cast the equivalent of 1,000 common stock votes for each Series A Preferred Stock held of record.

On May 9, 2023, the Company filed a second certificate of amendment to the designations, preferences, and rights of the Company's series A preferred stock, the amendment being the series A preferred stock is now convertible into common stock at a one-for-one basis.

Effective June 6, 2018 the Company filed a certificate of designation with the Nevada Secretary of State establishing a class of preferred stock named the Series B Preferred Stock, with 2,000,000 shares authorized at \$0.001 par value per share and setting forth its respective rights, preferences and limitations.

The holder of the Series B Preferred Stock shall at their option convert the shares of Series B Preferred Stock into shares of common stock on a one for one hundred fifty basis. The Series B Preferred Stock are anti-dilutive to reverse splits, and therefore in the case of a reverse split, are convertible to the number of common shares after the reverse split as would have been equal to the conversion rate of one-to-one.

Holder of outstanding shares of Series B Preferred Stock have no voting rights with common shareholders for each Series B Preferred Stock held of record.

Effective June 6, 2018, the Company filed a certificate of designation with the Nevada Secretary of State establishing a class of preferred stock named the Series C Preferred Stock, with 2,000,000 shares authorized at \$0.001 par value per share and setting forth its respective rights, preferences and limitations.

The holder of the Series C Preferred Stock shall at their option convert the shares of Series C Preferred Stock into shares of common stock on a one for two hundred fifty basis. The Series C Preferred Stock are anti-dilutive to reverse splits, and therefore in the case of a reverse split, are convertible to the number of common shares after the reverse split as would have been equal to the conversion rate of one to one.

Holder of outstanding shares of Series C Preferred Stock have no voting rights with common shareholders for each Series C Preferred Stock held of record.

NOTE 6 – EQUITY TRANSACTIONS

On January 4, 2021, 1,000,000 shares of Series A Preferred Stock held by Arielle Tolchin were transferred to two persons:

500,000 shares of the Company's Series A Preferred Stock were issued to Dianna Kaplan and another 500,000 shares of the Company's Series A Preferred Stock were issued to Blue Ridge Enterprises LLC, an entity controlled by Donald Steinberg. As each share of the Company's Series A Preferred Stock gives the holder the right to vote equivalent to 1,000 shares of the Company's common stock per share of Series A Preferred Stock held, Kaplan and Blue Ridge Enterprises each acquired 500,000,000 votes, representing approximately 49.17% of the Company's outstanding voting stock each.

On January 6, 2021, Daniel Witzel received 30,000 shares as compensation for \$16,000 in services pertaining to updating the corporate website.

On January 11, 2021, a financial consultant was issued 5,000,000 restricted common shares at a value of \$.03 as compensation for a consulting contract. The shares were deemed earned in full upon issuance.

On January 15, 2021, Arman Tabatabaei was appointed to the board of directors and was issued 1,200,000 shares valued at \$60,000 as compensation.

On January 25, 2021, the Company acquired all outstanding interests in MJOG and SecureCapital, Inc., a California corporation, in a related transaction from our CEO and CFO, James Hancock, for \$100.

On January 27, 2021, Blue Ridge Enterprises LLC received 5,000,000 common shares at \$.03 per share as compensation for a consulting agreement. On January 27, 2021, Donald Steinberg was appointed as a director of the Company.

On January 29, 2021, the Company filed amended Articles of Incorporation with the Secretary of State of the State of Nevada to change its corporate name from SecurCapital Holdings Corp. to Marijuana Strategic Ventures, Inc. On June 14, 2021, FINRA processed this name change and a change in the Company's stock symbol from CQER to MVSI with publication in the daily list on June 11, 2021 and an effective date of June 14, 2021.

On April 19, 2021, Kimberly Borsa was issued 19,239 common shares for consulting services rendered to the Company pursuant to a service agreement.

On June 16, 2021, Kimberly Borsa was issued 192,390 common shares for consulting services rendered to the Company pursuant to a service agreement.

On August 30, 2021, 600,000 common shares previously issued to Arman Tabatabaei for services rendered to the Company as director, were cancelled per settlement agreement.

On September 29, 2021, Donna Richardson was issued 100,000 common shares pursuant to a subscription agreement.

On September 29, 2021, Robert and Donna Richardson were issued 100,000 common shares pursuant to a subscription agreement.

On October 5, 2021, Robert Richardson received 125,000 common shares at \$.20 per share as compensation per consulting agreement. On October 19, 2021, Jeramy and Marilyn Virgin were issued 100,000 common shares pursuant to a subscription agreement.

On December 8, 2021, James Hancock received 2,186,250 common shares at \$.0007 per share as compensation for conversion of convertible debt.

On February 7, 2022, the Company entered into a Consulting Agreement with Iconic Investors Relations granting 75,000 common shares to John Grosso, and 75,000 common shares to Cory Bataan in exchange for their services.

On March 2, 2022, the Company entered into a Consulting Agreement with Robert Richardson granting 125,000 common shares to Mr. Richardson in exchange for his services.

On March 2, 2022, the Company entered into a Board Resolution, granting Donald Steinberg 500,000 preferred shares, as compensation for his services to the Company.

On May 9, 2022, Dianna Kaplan was committed 1,093,125 common shares at \$.0007 per share as compensation for conversion of convertible debt.

On July 12, 2022, the Company issued 1,093,125 common shares previously committed to Dianna Kaplan in exchange for a debt conversion of previously held convertible debt on May 9, 2022.

On July 16, 2022, the Company entered into an agreement with Bruce Perlowin, to issue Mr. Perlowin 500,000 shares of common stock in exchange for his agreement to sell the domain "mushroominc.com" to MSVI.

The Preferred Shares previously held by Donald Steinberg and Blue Ridge Enterprises were transferred to Earth Onyx LLC in the amounts of 500,000 and 500,000 on July 25, 2022 and July 26, 2022, respectively.

On August 16, 2022, the Company issued 727,584 common shares at \$.0007 per share as compensation for conversion of convertible debt.

On November 30, 2022, the Company issued Gregory P. Bush 250,000 common shares, as compensation for his technical, marketing, and business consulting services to the Company. The shares were measured at \$0.03 per share, the fair market value of the shares as of the date of issuance.

On January 10, 2023, the Company issued 1 million common shares to Nicole Fey at \$0.025 per share Stock Purchase Agreement dated January 10, 2023. The Company received \$25,000 in total for this sale of its common stock.

On March 22, 2023, the Company issued 69,037 common shares to John Grosso, and 69,037 common shares to Cory Bataan in exchange for their investor relations services. The shares were measured at

\$0.0235 per share, the fair market value of the shares as of the date of issuance.

On March 23, 2023, the Company issued 200,000 common shares to Richard Hawkins in exchange for consulting services. The shares were measured at \$0.0235 per share, the fair market value of the shares as of the date of issuance.

On June 3, 2023, the Company committed 250,000 common shares valued at \$0.25 per share to Dr. Hyder Ali Khoja per Consulting Agreement dated June 3, 2023.

On June 3, 2023, the Company committed 250,000 common shares valued at \$0.25 per share to David Flores per Consulting Agreement dated June 3, 2023.

On July 7, 2023, the Company issued the 250,000 shares of common stock previously committed to Dr. Hyder Ali Khoja. On July 7, 2023, the Company issued the 250,000 shares of common stock previously committed to David Flores.

On September 8, 2023, the Company issued SRFL.LTD 250,000 shares of common stock in exchange for \$7,500 per Share Purchase Agreement signed and dated August 9, 2023. The funds were received by the Company on August 15, 2023.

On September 8, 2023, the Company issued Nicole Fey 250,000 shares of common stock in exchange for \$7,500 per Share Purchase Agreement signed and dated September 8, 2023. The funds were received by the Company on August 24, 2023.

On September 8, 2023, the Company issued Maqsad Suriev 200,000 shares of common stock valued at \$0.25 per share per Consulting Agreement signed and dated August 25, 2023.

On September 11, 2023, the Company issued Alicia Fantozzi 250,000 shares of common stock valued at \$0.25 per share per Consulting Agreement signed and dated August 25, 2023.

On April 12, 2024 the company issued 2,000,000 shares of the Company's Series A Preferred Stock to Kimberly Carlson. As each share of the Company's Series A Preferred Stock gives the holder the right to vote equivalent to 1,000 shares of the Company's common stock per share of Series A Preferred Stock held, Kimberly Carlson acquired 2,000,000,000 votes, representing approximately 57.14% of the Company's outstanding voting stock.

NOTE 7 – RELATED PARTY TRANSACTIONS

Management has evaluated related party transactions pursuant to the requirements of ASC Topic 850 and has determined that no material related party transactions exist through the date of this filing apart from the following: None noted.

NOTE 8 – SUBSEQUENT EVENTS

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855 and has determined that no material subsequent events exist through the date of this filing apart from the following: None noted.